If you’re doing well on a weekly GLP-1 shot, don’t switch to a pill just because it exists. The pill is a real option, but usually for someone the shot is failing, not someone it’s working for. Here’s how I decide between the two pills, and when I’d stay on the injection.
The two pills aren’t the same drug
Oral Wegovy is semaglutide, the same molecule as the weekly Wegovy shot, just packed into a tablet with an absorption helper. Foundayo is orforglipron: a different, smaller molecule that happens to hit the same receptor. Same target, different drug.
The semaglutide tablet comes with a ritual: first thing, empty stomach, no more than four ounces of water, then sit with it for thirty minutes before coffee, food, or any other morning pill.1 Miss the ritual and you absorb maybe a tenth of the dose. Foundayo has none of that. Take it whenever, with whatever.2 If that thirty-minute window is the thing keeping you off a GLP-1, Foundayo solves a real problem. If it isn’t, the convenience buys you less than you’d think.
How much weight you actually lose
Oral Wegovy has the stronger number. In OASIS 4 (2025), adults with obesity lost 13.6 percent of body weight at 64 weeks on the 25 mg tablet, against 2.4 percent on placebo.3 That’s in the same neighborhood as the weekly semaglutide shot, which landed around 14 percent in the head-to-head SURMOUNT-5 trial.7
Foundayo’s number comes with a caveat I want you to understand. The trial, ATTAIN-1 (2025), tested orforglipron at 36 mg and saw 11.2 percent weight loss at that top dose.4 But the FDA approved a maximum of 17.2 mg, roughly half that dose.2 The approved dose you can actually take falls between the 12 mg arm, where trial participants lost 8.4 percent, and the 36 mg arm. So expect something like 8 to 11 percent estimated weight loss.
Weekly tirzepatide still beats everything for raw weight loss. It beat the semaglutide shot head-to-head in SURMOUNT-5 (2025).7 If maximum weight loss is the goal, especially with severe obesity, an injectable is still the better tool. I wrote about that broader choice in the main GLP-1 article.
Tradeoff table: the pill choice is not just pill versus shot
| Option | Strongest reason | Main tradeoff | Best fit |
|---|---|---|---|
| Oral Wegovy | More weight loss than the approved Foundayo dose range, plus a cardiovascular indication | Strict empty-stomach dosing every morning | Needle aversion, cardiovascular disease, and a reliable morning routine |
| Foundayo | No food or water restrictions | Less direct weight-loss certainty at the approved max dose, and no CV outcomes indication | Daily pill preference when the semaglutide ritual is unrealistic |
| Weekly semaglutide shot | Strongest direct cardiovascular outcomes evidence in obesity | Injection, coverage, and supply friction | Established cardiovascular disease or a shot that is already working |
| Weekly tirzepatide shot | Highest weight-loss ceiling | No MACE indication yet and still an injection | When maximum weight loss is the main goal |
The part that actually separates them: your heart
This is where the two pills part ways, and it’s the part I weigh most heavily.
Semaglutide has cardiovascular evidence. SELECT (2023) showed the weekly shot cut heart attacks, strokes, and cardiovascular deaths in people with established heart disease and obesity.5 SOUL (2025) then showed the oral form, at the 14 mg diabetes dose, did the same in high-risk type 2 diabetes.6 The 25 mg tablet carries the heart-protection indication on its label by bridging from that evidence: same molecule, higher dose, same expected effect. That bridge is reasonable, but it is not direct proof; no cardiovascular outcomes trial has tested the 25 mg tablet itself.
Foundayo has no completed cardiovascular outcomes trial and no heart-protection indication.2 It lowers weight and improves blood pressure and lipids, and I’d be surprised if the class effect doesn’t show up for it eventually, but “I’d be surprised” is not “we tested it.” If you have established cardiovascular disease, I would not assume it gives the same heart protection as semaglutide.
The tradeoffs the pill ads skip
The easy story is that a pill is simpler. Sometimes. A daily pill is easier to miss than a once-weekly shot, and a missed semaglutide dose is a wasted one. “Easier to take” didn’t mean “easier to tolerate” for orforglipron either: in the one head-to-head trial (in diabetes, against a lower semaglutide dose), people on orforglipron had more GI side effects, quit more often, and their resting heart rate climbed a few more beats.2 Not a bad drug. Just not a free lunch.
Price is the other trap. Launch pricing, coupons, and self-pay programs aren’t what your insurer will actually cover at the maintenance dose. The number that matters is yours, after your formulary has had its say.
How I would choose among them
If your shot is working, covered, and tolerable, stay on it. That’s a good place to be, and novelty isn’t a reason to leave.
Oral Wegovy makes the most sense if you want to stay on semaglutide, the cardiovascular indication matters to you, and your mornings can absorb a thirty-minute fasting window. Foundayo makes more sense if that fasting window is the real barrier, injections are the reason you’re not treated, and your goal is meaningful, not maximal, weight loss.
The four questions to ask, in order: how much weight loss do you actually need? Do you have established cardiovascular disease? What will each option cost at the maintenance dose? And which routine will you still be following a year from now? The newest GLP-1 is not automatically the best one. The best one has enough evidence for your risk, enough effect for your goal, and a schedule you’ll actually keep.